Evidence map›Paper›PMID 29342270›Full record

ArticleThe Journal of antimicrobial chemotherapy2018

Whole-genome analysis reveals the evolution and transmission of an MDR DH/NAP11/106 Clostridium difficile clone in a paediatric hospital.

Larry K Kociolek, Egon A Ozer, Dale N Gerding, David W Hecht, Sameer J Patel, Alan R Hauser

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Phenotypic analysis of variousApplied and environmental microbiology · 2025
    Article
  3. Review
  4. Molecular epidemiology ofFrontiers in public health · 2022
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Larry K KociolekAnn & Robert H. Lurie Children's Hospital of Chicago, 225 E. Chicago Ave, Chicago, IL 60611, USA.
Egon A OzerNorthwestern University Feinberg School of Medicine, 320 E. Superior St, Chicago, IL 60611, USA.
Dale N GerdingLoyola University Chicago Stritch School of Medicine, 2160 S. 1st Ave, Maywood, IL 60153, USA.
David W HechtLoyola University Chicago Stritch School of Medicine, 2160 S. 1st Ave, Maywood, IL 60153, USA.
Sameer J PatelAnn & Robert H. Lurie Children's Hospital of Chicago, 225 E. Chicago Ave, Chicago, IL 60611, USA.
Alan R HauserNorthwestern University Feinberg School of Medicine, 320 E. Superior St, Chicago, IL 60611, USA.
Northwestern University · USLoyola University Chicago · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Population Analysis of Pseudomonas aeruginosa VirulenceR01AI118257 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2016 to 2025
$4.9M
Patient-Oriented Research on Pseudomonas aeruginosaK24AI104831 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2013 to 2024
$1.2M
Optimizing the diagnosis of pediatric Clostridium difficile infectionK23AI123525 · NIAID · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI KOCIOLEK, LARRY K · 2016 to 2020
$937k
NCATS NIH HHS UL1 TR001422NIAID NIH HHS K23 AI123525NIAID NIH HHS K24 AI104831NIAID NIH HHS R01 AI118257
6 · The paper itself

Abstract

Background: Clostridium difficile strain DH/NAP11/106, a relatively antibiotic-susceptible strain, is now the most common cause of C. difficile infection (CDI) among adults in the USA. Objectives: To identify mechanisms underlying the evolution and transmission of an MDR DH/NAP11/106 clone. Methods: WGS (Illumina MiSeq), restriction endonuclease analysis (REA) and antibiotic susceptibility testing were performed on 134 C. difficile isolates collected from paediatric patients with CDI over a 2 year period. Results: Thirty-one of 134 (23%) isolates were REA group DH. Pairwise single-nucleotide variant (SNV) analyses identified a DH clone causing seven instances of CDI in two patients. During the 337 days between the first and second CDI, Patient 1 (P1) received 313 days of antibiotic therapy. Clindamycin and rifaximin resistance, and reduced vancomycin susceptibility (MIC 0.5-2 mg/L), were newly identified in the relapsed isolate. This MDR clone was transmitted to Patient 2 (P2) while P1 and P2 received care in adjacent private rooms. P1 and P2 each developed two additional CDI relapses. Comparative genomics analyses demonstrated SNVs in multiple antibiotic resistance genes, including rpoB (rifaximin resistance), gyrB and a gene encoding PBP; gyrB and PBP mutations did not consistently confer a resistance phenotype. The clone also acquired a 46 000 bp genomic element, likely a conjugative plasmid, which contained ermB (clindamycin resistance). The element shared 99% identity with the genomic sequence of Faecalibacterium prausnitzii, an enteric commensal. Conclusions: These data highlight the emergence of MDR in C. difficile strain DH/NAP11/106 through multiple independent mechanisms probably as a consequence of profound antibiotic pressure.

Indexed as

Disease Transmission, InfectiousEvolution, MolecularGenotypeWhole Genome SequencingAdolescentChildChild, PreschoolClostridioides difficileClostridium InfectionsDNA-Directed RNA PolymerasesDNA GyraseDrug Resistance, Multiple, BacterialFemaleHospitals, PediatricHumansInfantDNA-Directed RNA PolymerasesDNA GyrasePenicillin-Binding ProteinsPHB2 protein, humanProhibitinsRNA polymerase beta subunit

Identifiers

PMID29342270
PMCPMC6454525
OpenAlexW2784007745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.